As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lexicon Pharmaceuticals Inc. The largest reported stake is Invus Global Management, LLC's, at 39.4%. 5 filings are on record since July 8, 2025 (Schedule 13D/A, May 8, 2026).
Sell to companies like Lexicon Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 66,739,266 · Shared voting: 0 · Sole dispositive: 66,743,390 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Holder: Fmr LLC · Percent: 11.7% · SCHEDULE 13G/A
- · Holder: Invus Global Management, LLC · Percent: 39.4% · SCHEDULE 13D/A
- · Holder: Invus Global Management, LLC · Percent: 36.2% · SCHEDULE 13D/A
- · Holder: Fmr LLC · Percent: 10.5% · SCHEDULE 13G/A
Lexicon Pharmaceuticals Inc has 5 Schedule 13D or 13G filings on record since 2025-07-08. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Invus Global Management, LLC | 39.4% | 42,765,057 | SCHEDULE 13D/A, 2026-05-08 | 2026-04-30 |
| Fmr LLC | 15% | 66,743,390 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
Holding shares or following this stake? See who's behind Lexicon Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Lexicon Pharmaceuticals Inc and the records around it.
Lexicon Pharmaceuticals Inc elsewhere on the record
- Company profile and every filing Feb 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- Invus, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Lexicon Pharmaceuticals Inc
Get an email when Lexicon Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lexicon Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lexicon Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexicon Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 66,739,266 | 0 | 66,743,390 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 66,743,390 | 0 | SCHEDULE 13G/A, 2026-11-05 |
The latest filing identifies Lexicon Pharmaceuticals Inc by CUSIP 528872302 and gives its principal executive office as 2445 TECHNOLOGY FOREST BLVD., SUITE 1100, THE WOODLANDS, TX 77381 (SCHEDULE 13G/A, 2026-11-05).
Purpose of Transaction (Item 4)
Invus Global Management, LLC
Item 4 of the Statement is hereby amended and supplemented as follows: As previously disclosed in Amendment No. 25, on February 2, 2026, Artal Participations S.a.r.l. acquired 367,145.12 shares of Preferred Stock, and on February 17, 2026 Artal Participations S.a r.l. purchased an additional 41,289.58 shares of Preferred Stock, in each case, pursuant to the terms of the Preferred Purchase Agreement. Each share of Preferred Stock would automatically convert into 50 shares (subject to adjustments) of Issuer Common Stock immediately following the satisfaction of all of the following conditions: (i) the approval of the New Charter by the shareholders of the Issuer at the Annual Meeting; (ii) the adoption of the New Charter by the Issuer's board of directors; and (iii) the filing and acceptance of the New Charter with and by the Secretary of State of the State of Delaware. On April 30, 2026, all conditions were met, and the 408,434.70 shares of Preferred Stock directly held by Artal Participations S.a.r.l. automatically converted into 20,421,735 shares of Issuer Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-05-08
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Fmr LLC | 10.5% | SCHEDULE 13G/A |
| 2026-02-02 | Invus Global Management, LLC | 36.2% | SCHEDULE 13D/A |
| 2026-05-08 | Invus Global Management, LLC | 39.4% | SCHEDULE 13D/A |
| 2026-08-06 | Fmr LLC | 11.7% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 15% | SCHEDULE 13G/A |
Questions about who owns Lexicon Pharmaceuticals Inc
Who owns Lexicon Pharmaceuticals Inc?
On this page, 2 holders' latest ownership filings report 5% or more of Lexicon Pharmaceuticals Inc: Invus Global Management, LLC (39.4%, Schedule 13D/A, filed 2026-05-08) and Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05).
Who are the largest shareholders of Lexicon Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Lexicon Pharmaceuticals Inc on this page are Invus Global Management, LLC (39.4%) and Fmr LLC (15%).
When did Invus Global Management, LLC buy into Lexicon Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from Invus Global Management, LLC on this page is the Schedule 13D/A, filed 2026-02-02, reporting 36.2%; its latest, Schedule 13D/A filed 2026-05-08, reports 39.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Lexicon Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Form D, private offering | $55.67M sold | Form D page | Source |
| January 28, 2019 | Court case: Manopla v. Lexicon Pharmaceuticals, Inc., District Court, S.D. Texas | — | Court records | Source |
| September 14, 2017 | Court case: Coding Technologies, LLC v. Lexicon Pharmaceuticals, Inc., District Court, S.D. Texas | — | Court records | Source |
| January 26, 2009 | Court case: Lexicon Pharmaceuticals, Inc. v. The University of Utah Research Foundation, District Court, S.D. Texas | — | Court records | Source |
Lexicon Pharmaceuticals Inc: every filing and event
Tools for this story
Each opens in a new tab, filled in for Lexicon Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.